BURLINGTON, ON, Aug. 2 /CNW/ - THE JENEX CORPORATION ("Jenex" or the
"Corporation") (TSX Venture Exchange - JEN), announced today they have
received CE Mark approval for their revolutionary interceptCS Cold Sore
Prevention System. This approval permits the Company to begin marketing
interceptCS in European Union (EU) countries and other countries around the
world that recognize the CE Mark approval process.
"We are very pleased to have received CE approval to market interceptCS,"
says Michael Jenkins, President and CEO of The Jenex Corporation. "The CE Mark
will allow Jenex the opportunity to access European markets, and other
international jurisdictions, with our revolutionary product for the prevention
of cold sores. This is a significant milestone and the first step towards
commercializing interceptCS in other major world markets."
It is estimated that there are between 45 million and 90 million
recurrent cold sore sufferers in the European community.
About The Jenex Corporation
Headquartered in Burlington, Ontario, the Corporation owns a patented
Thermal Therapy technology. Patents in the United States, Canada, Australia
and Europe protect the technology. interceptCS is the first product proven and
approved to prevent cold sores. More information about interceptCS can be
found at www.interceptCS.com
Forward Looking Statements
The TSX Venture Exchange Inc. has not reviewed and does not accept
responsibility for the accuracy or the contents of this press release. Certain
information included in this press release is forward-looking and is subject
to important risks and uncertainties. The results or events predicted in these
statements may differ materially from actual results or events.
For further information:
For further information: The Jenex Corporation, 207 - 940 Sheldon Court,
Burlington, Ontario, L7L 5K6, Michael A. Jenkins, President, Telephone: (905)
632-3830, Facsimile: (905) 632-3774, Email: firstname.lastname@example.org